In summary, our results provide in vivo evidence that afatinib stimulated weaker autophagy in CDH1-silenced tumors, which has the potential to be the intrinsic driving factor for selectively eradicating stem-like HNSCC cells. The gene discussed is CDH1; the disease is head and neck squamous cell carcinoma.